Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Oxfordshire based Director operating in the Medical space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Steve Lane
Commercial Director UK & Europe of Quanta
Follow Steve Lane:
About Quanta: Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Chris Jones
Non Executive Director & Special Advisor of MediSieve
Chris Jones joined Elasmogen as Executive Chairman in 2016.
Follow Chris Jones:
About Elasmogen, MediSieve, Mologic: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Gil McVean
Co Founder & Director of Genomics
Gil McVean is Professor of Statistical Genetics at the University of Oxford and Head of Bioinformatics and Statistical Genetics at the Wellcome Trust Centre for Human Genetics. After an undergraduate training in Zoology, he obtained a PhD with Laurence Hurst in Cambridge and worked with Brian and Deborah Charlesworth in Edinburgh before joining Oxford in 2000. His research focuses on understanding the molecular and evolutionary processes that shape genetic variation in populations and the relationship between genetic variation and phenotype. He has made contributions to our understanding of areas including recombination hotspots, historical patterns of natural selection, the male mutation rate, human genetic variation, the role of HLA in complex disease and genealogical processes. He has played a leading role in the HapMap and 1000 Genomes Projects and currently works on organisms from HIV to malaria.
Follow Gil McVean:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Oliver Kessler
Founder, Medical Director and Chief Medical Officer of Orthox Ltd.
Oliver Kessler is a practising knee surgeon based in Zurich with a strong track record of biomaterials research and a focus on meniscal and cartilage repair systems and joint kinematics. He spent 6 years at Stryker Orthopaedics as Director of Orthobiologics supervising a major meniscal tissue engineering programme. He has extensive contacts within both the orthopaedic industry and the surgical community and is responsible for overseeing clinical development of Orthox’s product pipeline.
Follow Oliver Kessler:
About Orthox Ltd.: Orthox develops tissue regenerative implants that address large injuries to cartilage tissues in which early osteoarthritis may be present.
Mick Hunter
Chief Scientific Officer & Director of Development of Atopix Therapeutics
Dr Mick Hunter has responsibility for drug discovery and development in Atopix. He has over 28 years experience in Pharmaceutical and Biotech R&D. He has spent the past 12 years working on the discovery and development of antinflammatory and respiratory drugs. He is also Director of Discovery at Oxagen Ltd. Mick has led Atopix CRTH2 antagonist discovery and development program from concept to Phase IIb. Less Mick has experience of leading teams to identify IND candidates and managing them through early clinical development. He is familiar with regulatory environments and has managed biological pilot plants for GMP manufacture. Prior to joining Atopix, Mick held positions at Oxagen Ltd, British Biotech Pharmaceuticals (now Vernalis PLC) and at Searle Pharmaceuticals.
Follow Mick Hunter:
About Atopix Therapeutics: Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK
